Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Valeant Pharma target lowered to $20 at Barclays (15.11 +0.19)Barclays lowers their VRX tgt to $20 from $34 noting VRX remains one of the most hotly debated stocks in their coverage as investors remain concerned about the company's leverage. Last summer saw some enthusiasm when VRX sent a constructive message on its ability to generate cash through potential divestitures. Shares slumped in the fall with VRX unable to close any deals, though they gained some short-lived traction in Jan when some non-core sales were finally announced. Those gains were given back when VRX outlined headwinds it faced in '17. <strong>Firm thinks it's possible, though not certain, for VRX to generate an additional $8bn from non-core but recognize this likely won't address all investor concerns, since VRX would remain leveraged at +6x EBITDA; firm suspects a more aggressive recapitalization may be needed; Equal Weight.</strong></td> </tr></table>"